2013
DOI: 10.1517/17460441.2013.843524
|View full text |Cite
|
Sign up to set email alerts
|

Development of aldose reductase inhibitors for the treatment of inflammatory disorders

Abstract: It is important that future efforts focus on delineating all the steps of the molecular mechanism that implicates ALR2 in inflammatory pathologies. At the same time, utilizing the previous efforts in the field of ARIs, several candidates that have been proven safe in the clinic may be evaluated for their clinical significance as anti-inflammatory medication. Finally, structurally novel ARIs, designed to target specifically the proinflammatory subpocket of ALR2, should be pursued.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
26
0

Year Published

2014
2014
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 43 publications
(26 citation statements)
references
References 126 publications
0
26
0
Order By: Relevance
“…Potential mechanisms are aberrant overexpression/activation of hepatic AR and/or Polyol Pathway (PP)-associated overt oxidative stress and inflammation, which are believed to contribute significantly to the development of cancers [ 4 , 13 , 14 ]. Studies also suggest that inhibition of oxidative stress or inflammation is helpful with cancer prevention or treatment.…”
Section: Introductionmentioning
confidence: 99%
“…Potential mechanisms are aberrant overexpression/activation of hepatic AR and/or Polyol Pathway (PP)-associated overt oxidative stress and inflammation, which are believed to contribute significantly to the development of cancers [ 4 , 13 , 14 ]. Studies also suggest that inhibition of oxidative stress or inflammation is helpful with cancer prevention or treatment.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, Ramana and Srivastava (2010) reviewed the implication of ALR2 in inflammatory pathologies, indicating the multiple roles of ALR2 inhibitors. Aldose reductase inhibitors were found to attenuate reactive oxygen species production both in vitro and in vivo (Chatzopoulou et al 2013). The correlation between LOX inhibition and ALR inhibition is implied by the fact that most of the LOX inhibitors are antioxidants or free radical scavengers, taking also into account the role of lipoxygenase in inflammatory pathologies (Muller 1994).…”
Section: Introductionmentioning
confidence: 99%
“…Lipid peroxidation-derived lipid aldehydes, such as 4-hydroxy-trans-2-nonenal (HNE), and their glutathione conjugates (e.g. GS-HNE), were found to be efficiently reduced by ALR2 to the corresponding alcohols DHN (1,4-dihydroxy-nonene) and GS-DHN (glutathionyl-1,4-dihydroxynonene), which mediate inflammatory signals 2 . ALR2 inhibitors, such as acetic acid derivatives (tolrestat, zenarestat), spiro hydantoins (sorbinil) or the succinimide class of compounds (ranirestat), have been primarily investigated for their role against diabetic complications [3][4][5][6][7][8] .…”
Section: Introductionmentioning
confidence: 99%